Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: The Radium-select Study [NA]
The Radium-select study, sponsored by The Netherlands Cancer Institute, is currently recruiting to investigate treatment options for metasta…
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) [Phase 3]
A Phase 3 China-cohort trial investigates combining olaparib with abiraterone as first-line therapy for men with metastatic castration-resis…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer [Phase 3]
Phase 3 trial update for acetylsalicylic acid (aspirin) and atorvastatin in patients with castration-resistant prostate cancer; recruitment …
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC) [Phase 2]
A Phase 2 clinical trial update evaluating metastasis-directed radiotherapy for oligoprogressive metastatic castration-resistant prostate ca…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)
This clinical trial update describes experiences administering Lutetium-177-PSMA-617 via a port reservoir (TIVAP). The study is currently re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC [Phase 2]
Phase 2 study of SHR3680 in combination with SHR3162 for metastatic castration-resistant prostate cancer has been terminated. The trial (NCT…
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma [Phase 1]
Phase 1 study of AMG 340 in metastatic castration-resistant prostate cancer was terminated. Results were posted on 2025-06-17.
-
CLINICAL_TRIALS approval · 2025-06-13Clinical Trial Update: Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
A pre-approval access, single-patient request for the niraparib and abiraterone acetate combination in metastatic castration-resistant prost…
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency [Phase 2]
A Phase 2 trial evaluating a combination of docetaxel, carboplatin, and rucaparib camsylate in metastatic castration-resistant prostate canc…
-
CLINICAL_TRIALS other · 2025-06-12Clinical Trial Update: Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
This announces a pre-approval single-patient expanded-access program for talazoparib (PF-06944076) in a patient with metastatic castration-r…
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate [Phase 1]
Phase 1 trial evaluating pembrolizumab with chemotherapy for locally advanced or metastatic small cell and neuroendocrine cancers of the uro…
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 2]
A Phase 2 study of BMS-986218 alone or with nivolumab plus docetaxel in metastatic castration-resistant prostate cancer has been terminated.…
-
CLINICAL_TRIALS trial_result · 2025-06-08Clinical Trial Update: Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) [Phase 1, Phase 2]
This Phase I/II trial of BN-Brachyury Vaccine, M7824, N-803, and Epacadostat in metastatic castration-resistant prostate cancer has complete…
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: HTL0039732 in Participants With Advanced Solid Tumours [Phase 1, Phase 2]
HTL0039732 is being evaluated in a Phase 1/2 study for multiple advanced solid tumours and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
This clinical trial update describes a Phase I study evaluating HSK46575 in patients with metastatic castration-resistant prostate cancer; r…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: ProsTIC Registry of Men Treated With PSMA Theranostics
This entry provides an update on the ProsTIC Registry, a study of men treated with PSMA theranostics for prostate cancer, which is currently…
-
CLINICAL_TRIALS trial_result · 2025-05-29Clinical Trial Update: Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy [Phase 1, Phase 2]
This update reports results from a Phase 1/2 study of NGM120 in combination therapy for patients with advanced solid tumors, including pancr…
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC [Phase 1, Phase 2]
This clinical trial entry updates on a Phase 1/2 study of 177Lu-NYM032 Injection for metastatic castration-resistant prostate cancer, noting…
-
CLINICAL_TRIALS trial_result · 2025-05-20Clinical Trial Update: 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression [Phase 1]
Phase 1 trial evaluating the PET imaging tracer 11C-YJH08 for detecting glucocorticoid receptor expression in prostate cancer; the study was…
-
FDA approval · 2025-05-19FDA Approved: ABIRATERONE ACETATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for abiraterone acetate from Mylan Pharmaceuticals, authorizing a generic version to be marketed. Ab…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]
Clinical trial update for Tulmimetostat DZR123 (CPI-0209) in adults with advanced solid tumors and various lymphomas. The study is in Phase …
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 [Phase 2]
This is a Phase 2 trial evaluating 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer. The study is currently re…
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]
Phase 1 clinical trial update evaluating the combination of Lutetium-177-PSMA-617 and olaparib in metastatic castration-resistant prostate c…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC [Phase 2]
Phase 2 clinical trial evaluating radiotherapy in combination with fluzopanib and abiraterone acetate for metastatic castration-resistant pr…
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer [Phase 1]
Phase 1 trial evaluating ARRx in combination with enzalutamide for metastatic castration-resistant prostate cancer was terminated, with resu…